Pharmarise Holdings Corporation (TYO:2796)
Japan · Delayed Price · Currency is JPY 523.00
-1.00 (-0.19%)
Jan 23, 2026, 3:30 PM JST
Pharmarise Holdings Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | 2016 - 2020 |
| 66,566 | 63,508 | 54,466 | 52,030 | 51,608 | 52,324 | Upgrade | |
Revenue Growth (YoY) | 14.65% | 16.60% | 4.68% | 0.82% | -1.37% | 2.54% | Upgrade |
Cost of Revenue | 57,285 | 54,542 | 46,017 | 43,896 | 43,491 | 44,256 | Upgrade |
Gross Profit | 9,281 | 8,966 | 8,449 | 8,134 | 8,117 | 8,068 | Upgrade |
Selling, General & Admin | 4,877 | 4,860 | 4,371 | 3,728 | 3,525 | 3,659 | Upgrade |
Amortization of Goodwill & Intangibles | 763 | 763 | 557 | 635 | 700 | 738 | Upgrade |
Other Operating Expenses | 3,048 | 3,048 | 2,605 | 2,332 | 2,371 | 2,417 | Upgrade |
Operating Expenses | 8,661 | 8,671 | 7,533 | 6,695 | 6,596 | 6,821 | Upgrade |
Operating Income | 620 | 295 | 916 | 1,439 | 1,521 | 1,247 | Upgrade |
Interest Expense | -233 | -178 | -66 | -55 | -65 | -75 | Upgrade |
Interest & Investment Income | 9 | 10 | 1 | 2 | 2 | 2 | Upgrade |
Other Non Operating Income (Expenses) | 65 | -10 | -19 | 44 | 58 | 54 | Upgrade |
EBT Excluding Unusual Items | 461 | 117 | 832 | 1,430 | 1,516 | 1,228 | Upgrade |
Gain (Loss) on Sale of Investments | - | 7 | 19 | 30 | - | -4 | Upgrade |
Gain (Loss) on Sale of Assets | 20 | 20 | -1 | -4 | 2 | 61 | Upgrade |
Asset Writedown | -224 | -258 | -296 | -393 | -218 | -51 | Upgrade |
Other Unusual Items | 85 | 124 | -411 | -14 | 21 | -32 | Upgrade |
Pretax Income | 342 | 10 | 143 | 1,049 | 1,321 | 1,202 | Upgrade |
Income Tax Expense | 495 | 390 | 485 | 702 | 864 | 782 | Upgrade |
Earnings From Continuing Operations | -153 | -380 | -342 | 347 | 457 | 420 | Upgrade |
Minority Interest in Earnings | 10 | 13 | -9 | -14 | -10 | 6 | Upgrade |
Net Income | -143 | -367 | -351 | 333 | 447 | 426 | Upgrade |
Net Income to Common | -143 | -367 | -351 | 333 | 447 | 426 | Upgrade |
Net Income Growth | - | - | - | -25.50% | 4.93% | -26.17% | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 11 | 9 | 9 | 9 | Upgrade |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 12 | 12 | 12 | Upgrade |
Shares Change (YoY) | 0.52% | 7.58% | -15.61% | 0.59% | 0.20% | -1.03% | Upgrade |
EPS (Basic) | -12.56 | -32.42 | -33.35 | 35.42 | 47.90 | 45.78 | Upgrade |
EPS (Diluted) | -12.56 | -32.42 | -33.35 | 26.86 | 36.22 | 34.59 | Upgrade |
EPS Growth | - | - | - | -25.83% | 4.70% | -25.31% | Upgrade |
Free Cash Flow | 611 | 674 | 2,242 | 2,140 | 334 | 1,437 | Upgrade |
Free Cash Flow Per Share | 53.67 | 59.53 | 213.04 | 171.61 | 26.94 | 116.15 | Upgrade |
Dividend Per Share | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | Upgrade |
Gross Margin | 13.94% | 14.12% | 15.51% | 15.63% | 15.73% | 15.42% | Upgrade |
Operating Margin | 0.93% | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% | Upgrade |
Profit Margin | -0.21% | -0.58% | -0.64% | 0.64% | 0.87% | 0.81% | Upgrade |
Free Cash Flow Margin | 0.92% | 1.06% | 4.12% | 4.11% | 0.65% | 2.75% | Upgrade |
EBITDA | 2,176 | 1,788 | 2,086 | 2,663 | 2,829 | 2,591 | Upgrade |
EBITDA Margin | 3.27% | 2.81% | 3.83% | 5.12% | 5.48% | 4.95% | Upgrade |
D&A For EBITDA | 1,556 | 1,493 | 1,170 | 1,224 | 1,308 | 1,344 | Upgrade |
EBIT | 620 | 295 | 916 | 1,439 | 1,521 | 1,247 | Upgrade |
EBIT Margin | 0.93% | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% | Upgrade |
Effective Tax Rate | 144.74% | 3900.00% | 339.16% | 66.92% | 65.41% | 65.06% | Upgrade |
Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.